4.2 Article

Airway Transplantation

期刊

THORACIC SURGERY CLINICS
卷 24, 期 1, 页码 97-+

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.thorsurg.2013.09.005

关键词

Trachea replacement; Tissue engineering; Allogenic transplantation; Immunosuppressive medication; Rejection

资金

  1. European Project [FP7-NMP- 2011-SMALL-5]
  2. Bio- materials for Tracheal Replacement in Age-related Cancer via a Humanly Engineered Airway [280584e2]
  3. ALF medicine (Stockholm County Council), Transplantation of Bioengineered Trachea in Humans [LS1101e0042]
  4. Swedish Heart-Lung Foundation, Trachea Tissue Engineering
  5. Doctor Dorka Stiftung (Hannover, Germany), bioengineering of tracheal tissue
  6. Russian Ministry of Education and Science [11.G34.31.0065]

向作者/读者索取更多资源

No definitive solution has been discovered for replacing long segments or the entire trachea in humans. Most of this challenge stems from the specific function and mechanics that are almost impossible to replicate except in the setting of an allotransplantation, which requires lifelong immunosuppressive medication. Recently, tissue engineering provided significant evidence concerning the next promising therapeutic alternative for tracheal replacement. Underlying mechanism and pathways of cell-surface interactions, cell migration, and differentiation are essential to understand the complexity of tracheal tissue regeneration. Tracheal replacement remains challenging but initial steps toward an ideal therapeutic concept have been made.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据